PURPOSE: We explored the impact of obesity, body composition, and genetic polymorphisms on the pharmacokinetics (PK) of daunorubicin in children with cancer. PATIENTS AND METHODS: Patients ≤21 years receiving daunorubicin as an infusion of any duration <24 h for any type of cancer were eligible. Plasma drug concentrations were measured by high-performance liquid chromatography. Body composition was measured by dual-energy X-ray absorptiometry. Obesity was defined as a BMI >95% for age or as body fat >30%. NONMEM was used to perform PK model fitting. The Affymetrix DMET chip was used for genotyping. The impact of genetic polymorphisms was investigated using SNP/haplotype association analysis with estimated individual PK parameters. RESULTS: A total of 107 subjects were enrolled, 98 patients had PK sampling, and 50 patients underwent DNA analysis. Population estimates for daunorubicin clearance and volume of distribution were 116 L/m(2)/h ± 14% and 68.1 L/m(2) ± 24%, respectively. Apparent daunorubicinol clearance and volume of distribution were 26.8 L/m(2)/h ± 5.6% and 232 L/m(2) ± 10%, respectively. No effect of body composition or obesity was observed on PK. Forty-four genes with variant haplotypes were tested for association with PK. FMO3-H1/H3 genotype was associated with lower daunorubicin clearance than FMO3-H1/H1, p = 0.00829. GSTP1*B/*B genotype was also associated with lower daunorubicin clearance compared to GSTP1*A/*A, p = 0.0347. However, neither of these associations was significant after adjusting for multiple testing by either Bonferroni or false discovery rate correction. CONCLUSIONS: We did not detect an effect of body composition or obesity on daunorubicin PK. We found suggestive associations between FMO3 and GSTP1 haplotypes with daunorubicin PK that could potentially affect efficacy and toxicity.
PURPOSE: We explored the impact of obesity, body composition, and genetic polymorphisms on the pharmacokinetics (PK) of daunorubicin in children with cancer. PATIENTS AND METHODS: Patients ≤21 years receiving daunorubicin as an infusion of any duration <24 h for any type of cancer were eligible. Plasma drug concentrations were measured by high-performance liquid chromatography. Body composition was measured by dual-energy X-ray absorptiometry. Obesity was defined as a BMI >95% for age or as body fat >30%. NONMEM was used to perform PK model fitting. The Affymetrix DMET chip was used for genotyping. The impact of genetic polymorphisms was investigated using SNP/haplotype association analysis with estimated individual PK parameters. RESULTS: A total of 107 subjects were enrolled, 98 patients had PK sampling, and 50 patients underwent DNA analysis. Population estimates for daunorubicin clearance and volume of distribution were 116 L/m(2)/h ± 14% and 68.1 L/m(2) ± 24%, respectively. Apparent daunorubicinol clearance and volume of distribution were 26.8 L/m(2)/h ± 5.6% and 232 L/m(2) ± 10%, respectively. No effect of body composition or obesity was observed on PK. Forty-four genes with variant haplotypes were tested for association with PK. FMO3-H1/H3 genotype was associated with lower daunorubicin clearance than FMO3-H1/H1, p = 0.00829. GSTP1*B/*B genotype was also associated with lower daunorubicin clearance compared to GSTP1*A/*A, p = 0.0347. However, neither of these associations was significant after adjusting for multiple testing by either Bonferroni or false discovery rate correction. CONCLUSIONS: We did not detect an effect of body composition or obesity on daunorubicin PK. We found suggestive associations between FMO3 and GSTP1 haplotypes with daunorubicin PK that could potentially affect efficacy and toxicity.
Authors: R Sharma; S S Singhal; J Cheng; Y Yang; A Sharma; P Zimniak; S Awasthi; Y C Awasthi Journal: Arch Biochem Biophys Date: 2001-07-15 Impact factor: 4.013
Authors: A Romero; M Martín; B Oliva; J de la Torre; V Furio; M de la Hoya; J A García-Sáenz; A Moreno; J M Román; E Diaz-Rubio; T Caldés Journal: Ann Oncol Date: 2011-11-02 Impact factor: 32.976
Authors: C Sweeney; G Y McClure; M Y Fares; A Stone; B F Coles; P A Thompson; S Korourian; L F Hutchins; F F Kadlubar; C B Ambrosone Journal: Cancer Res Date: 2000-10-15 Impact factor: 12.701
Authors: Georg Hempel; Mary V Relling; Giulio de Rossi; Jan Stary; Paola De Lorenzo; Maria Grazia Valsecchi; Elena Barisone; Joachim Boos; Rob Pieters Journal: Pediatr Blood Cancer Date: 2010-03 Impact factor: 3.167
Authors: Patrick A Thompson; Gary L Rosner; Katherine K Matthay; Theodore B Moore; Lisa R Bomgaars; Kenneth J Ellis; Jamie Renbarger; Stacey L Berg Journal: Cancer Chemother Pharmacol Date: 2008-11-20 Impact factor: 3.333
Authors: Mina Nikanjam; Edmund V Capparelli; Jeffrey E Lancet; Arthur Louie; Gary Schiller Journal: Cancer Chemother Pharmacol Date: 2017-11-22 Impact factor: 3.333
Authors: Swantje Völler; Joachim Boos; Miriam Krischke; Gudrun Würthwein; Nina E Kontny; Alan V Boddy; Georg Hempel Journal: Clin Pharmacokinet Date: 2015-11 Impact factor: 6.447
Authors: Michael Michael; Winston Liauw; Sue-Anne McLachlan; Emma Link; Annetta Matera; Michael Thompson; Michael Jefford; Rod J Hicks; Carleen Cullinane; Athena Hatzimihalis; Ian G Campbell; Simone Rowley; Phillip J Beale; Christos S Karapetis; Timothy Price; Mathew E Burge Journal: Cancer Chemother Pharmacol Date: 2021-03-23 Impact factor: 3.333
Authors: Xia Sheng; Jean-Hugues Parmentier; Jonathan Tucci; Hua Pei; Omar Cortez-Toledo; Christina M Dieli-Conwright; Matthew J Oberley; Michael Neely; Etan Orgel; Stan G Louie; Steven D Mittelman Journal: Mol Cancer Res Date: 2017-11-08 Impact factor: 5.852
Authors: Christine Y Lu; Marc S Williams; Geoffrey S Ginsburg; Sengwee Toh; Jeff S Brown; Muin J Khoury Journal: Genet Med Date: 2017-08-10 Impact factor: 8.822
Authors: Mariamena Arbitrio; Maria Teresa Di Martino; Francesca Scionti; Giuseppe Agapito; Pietro Hiram Guzzi; Mario Cannataro; Pierfrancesco Tassone; Pierosandro Tagliaferri Journal: Oncotarget Date: 2016-08-16